Professional Documents
Culture Documents
Approach To The Patient With Suspected Immunodeficiency - Immunology Allergic Disorders - Merck Manuals Professional Edition
Approach To The Patient With Suspected Immunodeficiency - Immunology Allergic Disorders - Merck Manuals Professional Edition
Merck Manual Professional Version
Severe
Complicated
In multiple locations
Resistant to treatment
Initially, infections due to immunodeficiency are typically upper and lower respiratory tract
infections (eg, sinusitis, bronchitis, pneumonia) and gastroenteritis, but they may be serious
bacterial infections (eg, meningitis, sepsis).
Immunodeficiency should also be suspected in infants or young children with chronic diarrhea
and failure to thrive, especially when the diarrhea is caused by unusual viruses (eg, adenovirus)
or fungi (eg, Cryptosporidium sp). Other signs include skin lesions (eg, eczema, warts, abscesses,
pyoderma, alopecia), oral or esophageal thrush, oral ulcers, and periodontitis.
Less common manifestations include severe viral infection with herpes simplex or varicella
zoster virus and CNS problems (eg, chronic encephalitis, delayed development, seizure disorder).
Frequent use of antibiotics may mask many of the common symptoms and signs.
Immunodeficiency should be considered particularly in patients with infections and an
autoimmune disorder (eg, hemolytic anemia, thrombocytopenia).
Evaluation
History and physical examination are helpful but must be supplemented by immune function
testing. Prenatal testing is available for many disorders and is indicated if there is a family history
of immunodeficiency and the mutation has been identified in family members.
History
Clinicians should determine whether patients have a history of risk factors for infection or of
symptoms and risk factors for secondary immunodeficiency disorders. Family history is very
important.
Onset before age 6 mo suggests a T-cell defect because maternal antibodies are usually
protective for the first 6 to 9 mo.
Onset between the age of 6 and 12 mo may suggest combined B- and T-cell defects or a B-
cell defect, which becomes evident when maternal antibodies are disappearing (at about
age 6 mo).
In general, the earlier the age at onset in children, the more severe the immunodeficiency. Often,
certain other primary immunodeficiencies (eg, common variable immunodeficiency [CVID]) do
not manifest until adulthood.
Certain infections suggest certain immunodeficiency disorders ( Some Clues in Patient History to
Type of Immunodeficiency); however, no infection is specific to any one disorder, and certain
common infections (eg, respiratory viral or bacterial infections) occur in many.
Some Clues in Patient History to Type of Immunodeficiency
Finding Immunodeficiency
Familial clustering of autoimmune disorders (eg, SLE, RA, Common variable immunodeficiency or selective IgA
pernicious anemia) deficiency
Physical examination
Patients with immunodeficiency may or may not appear chronically ill. Macular rashes, vesicles,
pyoderma, eczema, petechiae, alopecia, or telangiectasia may be evident.
Cervical lymph nodes and adenoid and tonsillar tissue are typically very small or absent in X-
linked agammaglobulinemia, X-linked hyper-IgM syndrome, severe combined immunodeficiency
(SCID), and other T-cell immunodeficiencies despite a history of recurrent infections. In certain
other immunodeficiencies (eg, chronic granulomatous disease), lymph nodes of the head and
neck may be enlarged and suppurative.
Tympanic membranes may be scarred or perforated. The nostrils may be crusted, indicating
purulent nasal discharge. Chronic cough is common, as are lung crackles, especially in adults
with CVID. The liver and spleen are often enlarged in patients with CVID or chronic
granulomatous disease. Muscle mass and fat deposits of the buttocks are decreased. In infants,
skin around the anus may break down because of chronic diarrhea. Neurologic examination may
detect delayed developmental milestones or ataxia.
Other characteristic findings tentatively suggest a clinical diagnosis (see Characteristic Clinical
Findings in Some Primary Immunodeficiency Disorders).
Characteristic Clinical Findings in Some Primary Immunodeficiency Disorders
Age
Findings* Disorder
Group
< 6 mo
Cyanosis, a congenital heart disorder, midline liver Congenital asplenia
Adapted from Stiehm, ER, Conley ME: Immunodeficiency diseases: General considerations, in Immunodeficiency Disease
in Infants and Children, ed 4, edited by ER Stiehm. Philadelphia, WB Saunders Company, 1996, p. 212.
Initial testing
Tests are needed to confirm a diagnosis of immunodeficiency ( Initial and Additional Laboratory
Tests for Immunodeficiency). Initial screening tests should include
Quantitative Ig measurements
Antibody titers
Sweat test
Neutrophil chemotaxis
C3 level
C4 level
Complement CH50 activity (for total activity of the classical pathway) and
Specific component assays
deficiency AH50 activity (for total activity of the alternate complement
pathways)
BTK = Bruton tyrosine kinase; C = complement; CH = hemolytic complement; NEMO = nuclear factor–kappa-B essential
modulator; SCID = severe combined immunodeficiency; TREC = T-cell receptor excision circle.
If results are normal, immunodeficiency (especially Ig deficiency) can be excluded. If results are
abnormal, further tests in specialized laboratories are needed to identify specific deficiencies. If
chronic infections are objectively documented, initial and specific tests may be done
simultaneously. If clinicians suspect that immunodeficiency may be still developing, tests may
need to be repeated, with monitoring over time, before a definitive diagnosis is made.
CBC can detect abnormalities in one or more cell types (eg, WBCs, platelets) characteristic of
specific disorders, as in the following:
Neutropenia (absolute neutrophil count < 1200 cells/μL) may be congenital or cyclic or may
occur in aplastic anemia.
Lymphopenia (lymphocytes < 2000/μL at birth, < 4500/μL at age 9 mo, or < 1000/μL in
older children or adults) suggests a T-cell disorder because 70% of circulating lymphocytes
are T cells.
Leukocytosis that persists between infections may occur in leukocyte adhesion deficiency.
Anemia may suggest anemia of chronic disease or autoimmune hemolytic anemia, which
may occur in CVID and other immunodeficiencies.
However, many abnormalities are transient manifestations of infection, drug use, or other
factors; thus, abnormalities should be confirmed and followed.
Peripheral blood smear should be examined for Howell-Jolly bodies and other unusual RBC
forms, which suggest primary asplenia or impaired splenic function. Granulocytes may have
morphologic abnormalities (eg, giant granules in Chédiak-Higashi syndrome).
Quantitative serum Ig levels are measured. Low serum levels of IgG, IgM, or IgA suggest
antibody deficiency, but results must be compared with those of age-matched controls. An IgG
level < 200 mg/dL usually indicates significant antibody deficiency, although such levels may
occur in protein-losing enteropathies or nephrotic syndrome.
IgM antibodies can be assessed by measuring isohemagglutinin titers (anti-A, anti-B). All
patients except infants < 6 mo and people with blood type AB have natural antibodies at a titer of
≥ 1:8 (anti-A) or ≥ 1:4 (anti-B). Antibodies to blood groups A and B and to some bacterial
polysaccharides are selectively deficient in certain disorders (eg, Wiskott-Aldrich syndrome,
complete IgG2 deficiency).
IgG antibody titers can be assessed in immunized patients by measuring antibody titers before
and after administration of vaccine antigens ( Haemophilus influenzae type B, tetanus, diphtheria,
conjugated or nonconjugated pneumococcal, and meningococcal antigens); a less-than-twofold
increase in titer at 2 to 3 wk suggests antibody deficiency regardless of Ig levels. Natural
antibodies (eg, antistreptolysin O, heterophil antibodies) may also be measured.
With skin testing, most immunocompetent adults, infants, and children react to 0.1 mL of
Candida albicans extract (1:100 for infants and 1:1000 for older children and adults) injected
intradermally. Positive reactivity, defined as erythema and induration > 5 mm at 24, 48, and 72 h,
excludes a T-cell disorder. Lack of response does not confirm immunodeficiency in patients with
no previous exposure to Candida.
Chest x-ray may be useful in some infants; an absent thymic shadow suggests a T-cell disorder,
especially if the x-ray is obtained before onset of infection or other stresses that may shrink the
thymus. Lateral pharyngeal x-ray may show absence of adenoidal tissue.
Additional testing
If clinical findings or initial tests suggest a specific disorder of immune cell or complement
function, other tests are indicated.
If patients have recurrent infections and lymphopenia, lymphocyte phenotyping using flow
cytometry and monoclonal antibodies to T, B, and natural killer (NK) cells is indicated to check for
lymphocyte deficiency.
If cellular immunity deficiency is suspected, the T-cell receptor excision circle (TREC) test can be
done to identify infants with low T-cell counts. If tests show that T cells are low in number or
absent, in vitro mitogen stimulation studies are done to assess T-cell function. If MHC antigen
deficiency is suspected, serologic (not molecular) HLA typing is indicated. Some experts
recommend screening all neonates with a TREC test; testing is done routinely in some US states.
If humoral immunity deficiency is suspected, patients may be tested for specific mutations—for
example, in the genes that encode for Bruton tyrosine kinase (BTK), CD40 and CD40 ligand, and
nuclear factor-kappa-B essential modulator (NEMO). A sweat test is typically done during the
evaluation to rule out cystic fibrosis.
If combined cellular and humoral immunity is impaired and SCID is suspected, patients can be
tested for certain typical mutations (eg, in the IL-2 receptor γ [ IL-2RG , or IL-2Rγ ] gene).
If phagocytic cell defects are suspected, CD15 and CD18 are measured by flow cytometry and
neutrophil chemotaxis is tested. A flow cytometric oxidative (respiratory) burst assay (measured
by dihydrorhodamine 123 [DHR] or nitroblue tetrazolium [NBT]) can detect whether O2 radicals
are produced during phagocytosis; no production is characteristic of chronic granulomatous
disease.
If the type or pattern of infections suggests complement deficiency, the serum dilution required
to lyse 50% of antibody-coated RBCs is measured. This test (called CH50) detects complement
component deficiencies in the classical complement pathway but does not indicate which
component is abnormal. A similar test (AH50) can be done to detect complement deficiencies in
the alternative pathway.
T-cell deficiency
RBC adenosine deaminase assay Severe lymphopenia Levels are low in a specific form of SCID.
Complement deficiency
‡Test uses anti-CD3 for all T cells, anti-CD4 for helper T cells, anti-CD8 for cytotoxic T cells, anti-CD45RO or anti-CD45RA
for activated and naive T cells, anti-CD25 for regulatory T cells, and anti-CD16 and anti-CD56 for natural killer cells.
BTK = Bruton tyrosine kinase; CH = hemolytic complement; MHC = major histocompatibility complex; NADPH =
nicotinamide adenine dinucleotide phosphate; NEMO = NF-κB essential modifier; NF-κB = nuclear factor-kappa-B; SAP =
SLAM-associated protein; SCID = severe combined immunodeficiency; SLAM = signaling lymphocyte activation molecule.
Prenatal diagnosis
Prognosis
Prognosis depends on the primary immunodeficiency disorder. Most patients with an Ig or a
complement deficiency have a good prognosis with a near-normal life expectancy if they are
diagnosed early, are treated appropriately, and have no coexisting chronic disorders (eg,
pulmonary disorders such as bronchiectasis). Other immunodeficient patients (eg, those with a
phagocytic cell defect or combined immunodeficiencies, such as Wiskott-Aldrich syndrome or
ataxia-telangiectasia) have a guarded prognosis; most require intensive and frequent treatment.
Some immunodeficient patients (eg, those with SCID) die during infancy unless immunity is
provided through transplantation. All forms of SCID could be diagnosed at birth if a WBC count
and manual differential of cord or peripheral blood were routinely done in neonates. Suspicion
for SCID, a true pediatric emergency, must be high because prompt diagnosis is essential for
survival. If SCID is diagnosed before patients reach age 3 mo, transplantation of bone marrow or
stem cells from a matched or half-matched (haploidentical) relative is lifesaving in 95%.
To prevent early death, strongly consider screening all neonates for SCID using a T-cell
receptor excision circle (TREC) test.
Treatment
Vaccines and avoidance of exposure to infection
Treatment generally involves preventing infection, managing acute infection, and replacing
missing immune components when possible.
Infection prevention
Infection can be prevented by advising patients to avoid environmental exposures and not giving
them live-virus vaccines (varicella, rotavirus, measles, mumps, rubella).
Patients at risk of serious infections (eg, those with SCID, chronic granulomatous disease,
Wiskott-Aldrich syndrome, or asplenia) or of specific infections (eg, with Pneumocystis jirovecii in
patients with T-cell disorders) can be given prophylactic antibiotics (eg, 5 mg/kg
trimethoprim/sulfamethoxazole po bid).
To prevent graft-vs-host disease after transfusions, clinicians should use blood products from
cytomegalovirus-negative donors; the products should be filtered to remove WBCs and irradiated
(15 to 30 Gy).
After appropriate cultures are obtained, antibiotics that target likely causes should be given
promptly. Sometimes surgery (eg, to drain abscesses) is needed. Usually, self-limited viral
infections cause severe persistent disease in immunocompromised patients. Antivirals (eg,
amantadine, rimantadine, oseltamivir, or zanamivir for influenza; acyclovir for herpes simplex
and varicella-zoster infections; ribavirin for respiratory syncytial virus or parainfluenza 3
infections) may be lifesaving.
Such replacement helps prevent infection. Therapies used in more than one primary
immunodeficiency disorder include the following:
IV immune globulin (IVIG) is effective replacement therapy in most forms of antibody
deficiency. The usual dose is 400 mg/kg once/mo; treatment is begun at a low infusion rate.
Some patients need higher or more frequent doses. IVIG 800 mg/kg once/mo helps some
antibody-deficient patients who do not respond well to conventional doses, particularly
those with a chronic lung disorder. High-dose IVIG aims to keep IgG trough levels in the
normal range (> 600 mg/dL). IVIG may also be given by slow sc infusions at weekly intervals
with a starting dose of 100 mg/kg.
Hematopoietic stem cell transplantation using bone marrow, cord blood, or adult
peripheral blood stem cells is effective for lethal T-cell and other immunodeficiencies.
Pretransplantation chemotherapy is unnecessary in patients without T cells (eg, those with
SCID). However, patients with intact T-cell function or partial T-cell deficiencies (eg, Wiskott-
Aldrich syndrome, combined immunodeficiency with inadequate but not absent T-cell
function) require pretransplantation chemotherapy to ensure graft acceptance. When a
matched sibling donor is unavailable, haploidentical bone marrow from a parent can be
used. In such cases, mature T cells that cause graft-vs-host disease must be rigorously
depleted from parental marrow before it is given. Umbilical cord blood from an HLA-
matched sibling can also be used as a source of stem cells. In some cases, bone marrow or
umbilical cord blood from a matched unrelated donor can be used, but after
transplantation, immunosuppressants are required to prevent graft-vs-host disease, and
their use delays restoration of immunity.
Retroviral vector gene therapy has been successful in a few patients with X-linked and ADA-
deficient SCID, but this treatment is not widely used because some patients with X-linked SCID
developed leukemia.
Key Points
Consider a primary immunodeficiency if infections are unusually frequent or severe,
particularly if they occur in family members, or if patients have thrush, oral ulcers,
periodontitis, or certain skin lesions.
Do a complete physical examination, including the skin, all mucous membranes, lymph
nodes, spleen, and rectum.
Begin testing with CBC (with manual differential), quantitative Ig levels, antibody titers, and
skin testing for delayed hypersensitivity.
Select additional tests based on what type of immune defect is suspected (humoral,
cellular, phagocytic cell, or complement).
Test the fetus (eg, using fetal blood, chorionic villus sampling, or cultured amniotic cells) if
family members are known to have an immunodeficiency disorder.
Teach patients how to avoid infections, give indicated live-virus vaccines, and prescribe
prophylactic antibiotics for patients with certain disorders.
Consider IVIG for antibody deficiencies and hematopoietic stem cell transplantation for
severe immunodeficiencies, particularly T-cell immunodeficiencies.
© 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA